Cyclophosphamide (generic), Cytoxan

Cyclophosphamide (generic), Cytoxan Newswire (Page 6)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 6)

Results 101 - 120 of 260 in Cyclophosphamide (generic), Cytoxan

  1. Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs...Read the original story

    Jul 17, 2014 | Hispanic Business

    These results were published in the . Sixteen female dogs were enrolled in the clinical trial.

    Comment?

  2. Comparison of molecular and immunocytochemical methods for detection...Read the original story

    Jul 14, 2014 | BioMed Central

    Disseminated tumor cells have potential to predict the effect of adjuvant treatment.

    Comment?

  3. Immunosuppressive treatments in multiple sclerosis.Read the original story

    Jul 11, 2014 | CiteULike

    Multiple sclerosis is a heterogeneous autoimmune disorder of the central nervous system that is enigmatic, relapsing, and in some instances progressive.

    Comment?

  4. Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA...Read the original story

    Jul 10, 2014 | BioSpace

    Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA , Will Be Published In The Annals Of Oncology Lugano, Switzerland, July 10th, 2014: Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal trials for the investigational oral fixed-dose combination capsule ... (more)

    Comment?

  5. Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA...Read the original story

    Jul 10, 2014 | BioSpace

    LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal trials for the investigational oral fixed-dose combination capsule of netupitant 300 mg + oral palonosetron 0.50 mg , which is licensed to Eisai Inc. in the ... (more)

    Comment?

  6. Helsinn Announces That Phase 2/3 Pivotal Trials for NEPA (netupitant...Read the original story

    Jul 10, 2014 | Applied Clinical Trials

    Helsinn Announces That Phase 2/3 Pivotal Trials for NEPA , Will be Published in the Annals of Oncology Helsinn Announces That Phase 2/3 Pivotal Trials for NEPA , Will be Published in the Annals of Oncology Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal ... (more)

    Comment?

  7. A vaccine may cause pancreatic cancer to respond to immunotherapyRead the original story

    Jul 10, 2014 | PhysOrg Weblog

    Pancreatic ductal adenocarcinomas do not typically respond to immunotherapy, which limits treatment options for this cancer.

    Comment?

  8. Recent Findings from University of Helsinki Provide New Insights into ...Read the original story

    Jul 9, 2014 | Hispanic Business

    Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report.

    Comment?

  9. Natural Killer Cell Lymphomas Market Analysis, Size, Share, Trends and Forecast 2019Read the original story

    Jul 8, 2014 | SBWire

    Lymphoma is a common blood cancer type which develops when lymphocytes multiply in an uncontrolled manner.

    Comment?

  10. Chemotherapy-induced hepatitis B reactivation in lymphoma patients...Read the original story

    Jul 6, 2014 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  11. Spectrum Shares Up Following FDA Approval For Beleodaq; Tekmira'...Read the original story

    Jul 3, 2014 | Hispanic Business

    Accelerated Approval for Beleodaq -- In an 8-K filing on Wednesday, Spectrum reported that it gained accelerated approval for BeleodaqTM for Injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma .

    Comment?

  12. Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For BeleodaqRead the original story

    Jul 3, 2014 | Benzinga

    Shares of Spectrum Pharmaceuticals gained 5.7 percent following the U.S. Food and Drug Administration's approval of the New Drug Application for Beleodaq.

    Comment?

  13. Spectrum Pharmaceuticals Inc Files (8-K) Disclosing Regulation FD...Read the original story

    Jul 3, 2014 | Hispanic Business

    SPECTRUM PHARMACEUTICALS INC FILES Disclosing Regulation FD Disclosure, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Other Events, Financial Statements and Exhibits of their early action granting accelerated approval of the Company's New Drug Application for ... (more)

    Comment?

  14. Bone marrow transplantation shows potential for treating adults with sickle cell diseaseRead the original story

    Jul 1, 2014 | PhysOrg Weblog

    Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients with severe sickle cell disease, according to a study in the July 2 issue of JAMA .

    Comment?

  15. Stem cell transplantation for severe sclerosis linked with improved long-term survivalRead the original story w/Photo

    Jun 24, 2014 | Science Daily

    Among patients with a severe, life-threatening type of sclerosis, treatment with hematopoietic stem cell transplantation , compared to intravenous infusion of the chemotherapeutic drug cyclophosphamide, was associated with an increased treatment-related risk of death in the first year, but better long-term survival, according to a study.

    Comment?

  16. Janssen-Cilag International NV Submits EU Marketing Application For...Read the original story

    Jun 27, 2014 | BioSpace

    Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADEA to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma .

    Comment?

  17. Janssen Submits EU Marketing Application for VELCADEA (bortezomib) in Mantle Cell LymphomaRead the original story

    Jun 27, 2014 | Business Wire

    Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADEA to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma .

    Comment?

  18. Eisai Oncology & Helsinn Group to Present New CINV Research at 2014...Read the original story

    Jun 26, 2014 | Applied Clinical Trials

    The Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology will host this year's Symposium in "There is a need to study a new option for chemotherapy-induced nausea and vomiting prevention, despite the progress that has been made thus far," said , Ph.D., President, Oncology Product Creation Unit at Eisai Inc.

    Comment?

  19. Young researcher designs protector for people with Peritoneal DialysisRead the original story w/Photo

    Jun 25, 2014 | PhysOrg Weblog

    A lack of comfortable products for the safety of patients requiring peritoneal dialysis, administered to clean waste products from the blood when the kidneys fail, drove a student of the Higher Technological Institute of Choapas, Veracruz in the east coast of MA xico, to develop an ergonomic support allowing catheters inserted through the ... (more)

    Comment?

  20. A fifth of children visiting their doctor with a persistent cough could have whooping coughRead the original story

    Jun 24, 2014 | PhysOrg Weblog

    Whooping cough has been found in a fifth of UK school age children visiting their doctor with a persistent cough, even though most have been fully vaccinated, finds a study published in BMJ today.

    Comment?